Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

WHISH logo

The WHISH trial is a multi-centre multi-surgeon randomised controlled feasibility trial comparing standard wound dressings to Negative Pressure Wound Therapy (NPWT) dressings to establish the rate of deep infection in adult patients who have suffered a hip fracture requiring surgery.

The trial, which has just closed to recruitment, sought to recruit 464 patients over the age of 65 across five major trauma centres in the UK.

Recruitment went fantastically, with both patients and research sites keen to be involved, and took approximately 6 months. There is a 4 month follow up period for patients, and results will be released before the end of the year.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

The IMPROVE Trial team awarded inaugural Lelia Duley Prize for Patient-centred CLL Research

The IMPROVE trial team and scientific research group have just been awarded the inaugural Lelia Duley Prize for Patient-centred Chronic Lymphocytic Leukaemia Research.

NIHR fellowship to support national trial evaluating rehabilitation after kneecap dislocation

Dr Colin Forde has been awarded a National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Postdoctoral Award to lead a national study evaluating rehabilitation for people with a kneecap (patellar) dislocation.

Professor Laura Coates appointed Director of OCTRU

Professor Laura Coates has been appointed Director of the Oxford Clinical Trials Research Unit (OCTRU), where she will lead the next phase of its development and strengthen its position as a leading clinical trials unit.